



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
SEP 13 2002

TECH CENTER 1600/2900

Dkt.43016-A-PCT-US/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154 Examiner: Anne Holleran
Filed : November 16, 1995 Group Art Unit: 1642
For : GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

1185 Avenue of the Americas
New York, New York 10036
September 6, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with their duty of disclosure under 37 C.F.R. §1.56, Applicants direct the Examiner's attention to the following references, which are listed on accompanying form PTO-1449 (**Exhibit A**), copies of which are attached hereto as **Exhibits B-C**.

Wiegand et al., U.S. Patent No. 5,599,914, issued February 4, 1997, filed November 24, 1989 (**Exhibit B**).

Fiume, L. et al., Critical Reviews in Therapeutic Drug Carrier Systems, 4(4): 265-284, 1988 (**Exhibit C**).

These references were cited in Office Actions dated August 27, 2002 issued in two related applications (i.e., Serial No. 08/477,097 and Serial No. 08/475,784, respectively) to the present application. Applicants maintain that the subject references neither disclose nor suggest the invention claimed in the present application, whether viewed alone or in combination with any of the other cited references.

09/12/2002 MAHMED1 00000006 08196154

01 FC:126

180.00 OP

BEST AVAILABLE COPY

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154
Filed : November 16, 1995
Page 2

In accordance with 37 C.F.R. §1.97(e)(2), the undersigned certifies that no item of the information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' attorney invites the Examiner to telephone at the number provided below.

A fee of ONE HUNDRED EIGHTY DOLLARS (\$180.00) is deemed necessary in connection with this filing and a check for that amount is therefore enclosed. However, if any additional fee is required, authorization is hereby given to charge the amount of the required fee to Deposit Account No. 03-3125.

Respectfully submitted,

Mark A. Farley

John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Mark A. Farley 9-6-02
John P. White Date
Reg. No. 28,678
Mark A. Farley
Reg. No. 33,170

BEST AVAILABLE COPY